% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • jrus2010 jrus2010 Sep 18, 2010 12:38 PM Flag

    CC with Stifel

    They seemed to be deemphasizing previous indications and are now trying to highlight possible utility in prostate cancer. I'm kind of surprised they are putting most their eggs in the XL174 basket, as this is the compound that was just returned by BMS 2 years after they paid $200M upfront. Not a good sign. The new CEO is an R&D guy without a commercial background who was promoted after Scangos left for Biogen. Looks like they are going to plow forward and spend all the remaining money on a new potential indication for a failed compound.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.56-0.34(-5.76%)Sep 3 4:00 PMEDT